TET1 and urinary bladder carcinoma: Another study by Mao et al29 suggested that OCT3/4 may promote tumor immune evasion in bladder cancer by enhancing the TET1–nuclear factor erythroid 2-related factor 2 (NRF2)–MDM2 pathway.